RxDoctor Payments Data

Evan Pisick, MD

Hematology & Oncology · Zion, ILNPI 1427096700

Payments from drug & device makers

$449,969in general payments, 2019–2025

Across 71 payments — averaging $6337.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$275K
  • Pfizer$99K
  • Spectrum Pharmaceuticals Inc.$33K
  • Janssen Research & Development, LLC$29K
  • E.r. Squibb & Sons, L.L.C.$8K
  • Mirati Therapeutics, Inc.$5K
  • plus $424 from 9 others

What the payments were for

  • Food & beverage$47082%
  • Education$10018%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$449,969 in reported general payments places this provider in the 80th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$182,292
Medicare patients
541
Services billed
2,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide133$1,567,864
FruzaqlaFruquintinib18$457,980
ZejulaNiraparib Tosylate17$374,523
ErleadaApalutamide27$372,754
WeliregBelzutifan16$353,289
LonsurfTrifluridine/Tipiracil Hcl19$337,162
Abiraterone Acetate219$292,531
LorbrenaLorlatinib13$269,908
TagrissoOsimertinib Mesylate16$256,197
MektoviBinimetinib11$174,091
Everolimus13$78,826
EliquisApixaban87$57,444
MovantikNaloxegol Oxalate12$5,021
Megestrol Acetate30$2,147
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine33$1,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKZejula$19$374,52317 claims
MerckWelireg$114$353,28916 claims
PfizerLorbrena, Eliquis$98,826$327,352100 claims
AstraZenecaTagrisso$13$256,19716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Zion

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →